{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-023918","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.792927+00:00","generated_at":"2026-06-05T05:21:33.638874+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lyra Therapeutics doubles Executive Chair salary to $400k retroactive to Jan 1, 2024","bullets":["Board approved salary increase for Executive Chair Harlan Waksal from $200k to $400k annually.","Increase is retroactive to January 1, 2024.","No other compensation changes for officers were disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-023918","json":"https://secwatch.observer/filing/0000950170-24-023918.json","markdown":"https://secwatch.observer/filing/0000950170-24-023918.md","text":"https://secwatch.observer/filing/0000950170-24-023918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024023918/0000950170-24-023918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024023918/lyra-20240226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:21:33.638874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}